JP2025500971A5 - - Google Patents

Info

Publication number
JP2025500971A5
JP2025500971A5 JP2024538031A JP2024538031A JP2025500971A5 JP 2025500971 A5 JP2025500971 A5 JP 2025500971A5 JP 2024538031 A JP2024538031 A JP 2024538031A JP 2024538031 A JP2024538031 A JP 2024538031A JP 2025500971 A5 JP2025500971 A5 JP 2025500971A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500971A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/141670 external-priority patent/WO2023116925A1/en
Publication of JP2025500971A publication Critical patent/JP2025500971A/ja
Publication of JP2025500971A5 publication Critical patent/JP2025500971A5/ja
Pending legal-status Critical Current

Links

JP2024538031A 2021-12-24 2022-12-23 新規の抗tslp抗体 Pending JP2025500971A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021141294 2021-12-24
CNPCT/CN2021/141294 2021-12-24
CNPCT/CN2022/134293 2022-11-25
CN2022134293 2022-11-25
PCT/CN2022/141670 WO2023116925A1 (en) 2021-12-24 2022-12-23 Novel anti-tslp antibodies

Publications (2)

Publication Number Publication Date
JP2025500971A JP2025500971A (ja) 2025-01-15
JP2025500971A5 true JP2025500971A5 (cg-RX-API-DMAC7.html) 2026-01-06

Family

ID=86901374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538031A Pending JP2025500971A (ja) 2021-12-24 2022-12-23 新規の抗tslp抗体

Country Status (11)

Country Link
US (1) US20250051433A1 (cg-RX-API-DMAC7.html)
EP (1) EP4453030A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025500971A (cg-RX-API-DMAC7.html)
KR (1) KR20240128709A (cg-RX-API-DMAC7.html)
CN (1) CN118475607A (cg-RX-API-DMAC7.html)
AU (1) AU2022423383A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244178A1 (cg-RX-API-DMAC7.html)
IL (1) IL313679A (cg-RX-API-DMAC7.html)
MX (1) MX2024007966A (cg-RX-API-DMAC7.html)
TW (1) TW202337898A (cg-RX-API-DMAC7.html)
WO (1) WO2023116925A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗tslp抗體治療慢性鼻竇炎
WO2024238877A1 (en) 2023-05-18 2024-11-21 Medimmune, Llc Treatment of corticosteroid dependent asthma with anti-tslp antibody
AR134101A1 (es) * 2023-10-12 2025-12-03 Innovent Biologics Suzhou Co Ltd Anticuerpos anti-tslp y usos de los mismos
CN122295363A (zh) * 2023-11-22 2026-06-26 上海华奥泰生物药业股份有限公司 靶向tslp的抗原结合蛋白及应用
AU2024385129A1 (en) * 2023-11-22 2026-06-11 The United Bio-Technology (Hengqin) Co., Ltd. ANTI-IL-4Rα ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND BISPECIFIC ANTIBODY AND USE THEREOF
CN119735676B (zh) * 2023-12-26 2025-12-16 华润生物医药有限公司 抗tslp抗体及其用途
IL330343A (en) 2024-01-05 2026-08-01 Medimmune Llc Treatment of chronic obstructive pulmonary disease using an anti-TSLP antibody
AR135161A1 (es) 2024-01-29 2026-07-08 Astrazeneca Ab Composiciones de fragmentos de unión a la linfopoyetina estromal tímica (tslp) y métodos de uso de las mismas
WO2025195445A1 (zh) * 2024-03-21 2025-09-25 北京三诺佳邑生物技术有限责任公司 特异性结合light和tslp的多特异性抗体以及组合物及其应用
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2026101415A1 (en) * 2024-11-07 2026-05-15 Joint Stock Company ‘‘Biocad’’ Pharmaceutical composition of antibody to tslp

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP3842457A1 (en) * 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
US12435131B2 (en) * 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合tslp及びその使用
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途

Similar Documents

Publication Publication Date Title
JP2023075294A (ja) 抗cd47抗体及びその応用
AU2017328309B2 (en) Antibody specifically binding to PD-1 and functional fragment thereof
JP2019503687A (ja) 抗pd−l1抗体およびその使用
CN110066336B (zh) 抗cd47单克隆抗体、片段及其医药用途
EP3683234A1 (en) Il-6r antibody and antigen binding fragment thereof and medical use
JP7728595B2 (ja) 二重特異性抗体及びその用途
WO2021013065A1 (zh) 人源化抗VEGF Fab抗体片段及其用途
JP2024531462A (ja) Fap/cd40結合分子及びその医薬的使用
KR102571012B1 (ko) 항-il-22r 항체
JP7352007B2 (ja) ヒト化抗vegfモノクローナル抗体
CN120077072A (zh) Cldn18.2/4-1bb结合蛋白及其医药用途
KR20220079561A (ko) 항-줄기세포 인자 항체 및 이의 사용 방법
JP2024511027A (ja) 幹細胞因子抗体及びその使用方法
WO2019230869A1 (ja) 抗ヒトtlr7抗体
CN112805297B (zh) 抗人类pd-l1抗体及其用途
KR20220117307A (ko) 인간 il-13 및 il-17에 대해 결합 특이성을 갖는 다중 특이적 항체
JP2024543134A (ja) 修飾されたタンパク質又はポリペプチド
CA3019692A1 (en) Monovalent inhibitor of hutnfr1 interaction
TW202525846A (zh) 抗il—13多特異性抗體構築體及其用途
WO2020039049A1 (en) Anti-sirpg compounds
CN112480252A (zh) 抗白细胞介素-33抗体及其制备方法和应用
JP2019535236A (ja) テネイシンエピトープと抗体
RU2024117489A (ru) Новые антитела к TSLP
RU2844744C1 (ru) Антитела против фактора стволовых клеток и способы их применения
CN116199777B (zh) 抗hNKG2D抗体及其应用